Literature DB >> 27504926

The Availability of Ancillary Counseling in the Practices of Physicians Prescribing Buprenorphine.

Declan T Barry1, Tera Fazzino, Emily Necrason, Joel Ginn, Lynn E Fiellin, David A Fiellin, Brent A Moore.   

Abstract

OBJECTIVE: We set out to examine physicians' perceptions of the provision of ancillary services for opioid dependent patients receiving buprenorphine.
METHODS: An e-mail invitation describing the study was sent out by the American Society of Addiction Medicine to its membership (approximately 3700 physicians) and other entities (for a total of approximately 7000 e-mail addresses). E-mail recipients were invited to participate in a research study funded by the National Institutes on Drug Abuse involving completion of an online survey; 346 physicians completed the survey.
RESULTS: The majority of the 346 respondents were internal or family medicine (37%), or addiction medicine providers (30%), who were practicing in urban (57%) or suburban settings (27%). Most respondents reported either offering (66%) or referring patients for ancillary counseling (31%). Interventions that were most frequently offered or referrals provided were individual counseling (51%) and self-help groups (63%), respectively. Counseling availability differed significantly by provider specialization for any, individual, group, family or couples, and self-help groups.
CONCLUSIONS: Generally, respondents reported compliance with ancillary counseling requirements for buprenorphine treatment of opioid use disorder. In addition to examining the efficacy of a variety of ancillary counseling services for patients receiving opioid agonist treatment, further research should examine physicians' attitudes toward the role of such counseling in buprenorphine treatment. Although the study sample was relatively large, the generalizability of the findings is unclear, suggesting that further investigation of the availability of ancillary counseling in buprenorphine treatment among a larger nationally representative sample of providers may be warranted.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27504926      PMCID: PMC5042831          DOI: 10.1097/ADM.0000000000000247

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  22 in total

1.  Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction.

Authors:  Elizabeth C Katz; Barry S Brown; Robert P Schwartz; Kevin E O'Grady; Stuart D King; Devang Gandhi
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

Review 2.  Family therapy for drug abuse: review and updates 2003-2010.

Authors:  Cynthia L Rowe
Journal:  J Marital Fam Ther       Date:  2012-01

3.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

4.  Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

Authors:  David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld
Journal:  N Engl J Med       Date:  2006-07-27       Impact factor: 91.245

5.  A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification.

Authors:  Gregory S Brigham; Natasha Slesnick; Theresa M Winhusen; Daniel F Lewis; Xiamei Guo; Eugene Somoza
Journal:  Drug Alcohol Depend       Date:  2014-02-23       Impact factor: 4.492

6.  Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.

Authors:  Lydia Turner; Stefan P Kruszewski; G Caleb Alexander
Journal:  Am J Addict       Date:  2015-01

7.  The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up.

Authors:  Charles Ruetsch; Joseph Tkacz; Tracy L McPherson; John Cacciola
Journal:  Addict Behav       Date:  2012-01-25       Impact factor: 3.913

8.  Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.

Authors:  Andrew W Dick; Rosalie L Pacula; Adam J Gordon; Mark Sorbero; Rachel M Burns; Douglas Leslie; Bradley D Stein
Journal:  Health Aff (Millwood)       Date:  2015-06       Impact factor: 6.301

9.  Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.

Authors:  Richard S Schottenfeld; Marek C Chawarski; Mahmud Mazlan
Journal:  Lancet       Date:  2008-06-28       Impact factor: 79.321

10.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.

Authors:  W Ling; C Charuvastra; J F Collins; S Batki; L S Brown; P Kintaudi; D R Wesson; L McNicholas; D J Tusel; U Malkerneker; J A Renner; E Santos; P Casadonte; C Fye; S Stine; R I Wang; D Segal
Journal:  Addiction       Date:  1998-04       Impact factor: 6.526

View more
  4 in total

1.  The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice.

Authors:  Shashi N Kapadia; Judith L Griffin; Justine Waldman; Nicolas R Ziebarth; Bruce R Schackman; Czarina N Behrends
Journal:  Subst Use Misuse       Date:  2021-12-10       Impact factor: 2.164

Review 2.  A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder.

Authors:  Ashton E Clark; Shelby R Goodwin; Russell M Marks; Annabelle M Belcher; Emily Heinlein; Melanie E Bennett; Daniel J O Roche
Journal:  J Dual Diagn       Date:  2021-09-28

3.  Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Hannah K Knudsen
Journal:  Addict Behav       Date:  2019-01-16       Impact factor: 4.591

4.  Traditional Chinese medicine-facilitated treatments may relieve anxiety symptoms during drug switching from methadone to buprenorphine/naloxone for treating opioid dependence.

Authors:  Kai-Chiang Yu; Han-Ting Wei; Yuh-Hsiang Yeh; Chung-Hua Hsu
Journal:  BMJ Case Rep       Date:  2017-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.